期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单抗治疗B细胞非霍奇金淋巴瘤的耐药机制研究进展 被引量：1

Research advances of rituximab resistance in B-cell non-Hodgkin lymphoma
原文传递
导出
摘要 抗CD。单克隆抗体利妥昔单抗已经成为治疗B细胞非霍奇金淋巴瘤（NHL）的重要组成部分。尽管临床应用广泛，但肿瘤细胞对利妥昔单抗的耐药机制尚不明确。文章阐述了利妥昔单抗的作用机制、耐药的发生以及潜在的耐药机制，并对调节抗体、肿瘤细胞和宿主的免疫状况等克服耐药的方法进行了探讨。 Anti-CD20 monoclonal antibody rituximab has become an essential component of treatment regimens for B-cell non-Hodgkin lymphoma（NHL）. It is routinely incorporated into all phases of conventional treatment of B-cell NHL, but the precise mechanisms of action of rituximab in human remain unknown. This article will clarify the mechanisms of action of rituximab, the incidence and potential mechanisms of resistance. Finally, the novel approaches to modulate the antibody, the tumor cell, and the host immunologic environment to overcome rituximab resistance are discussed.
作者 吴剑秋(综述) 冯继锋(审校)
机构地区 江苏省肿瘤医院肿瘤内科
出处 《白血病．淋巴瘤》 CAS 2013年第5期312-314,共3页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 非霍奇金 单克隆抗体 免疫 耐药 Lymphoma, non-Hodgkin Monoelonal antibody Immunity Drug resistance
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood, 2010, 115: 5191-5201.
  • 2Weng WK, Weng WK, Levy R, et al. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical cou~c in patients with follicular lympboma. Leuk Lymphoma, 2009, 50: 1494-1500.
  • 3Farag SS, Flinn IW, Modali R, et al. Fe gamma Rma and Fe gamma R 11 a polymorphisms do not predict response to rituximab in B-cell chronic lymphoe.ytic leukemia. Blood, 2004, 103: 1472-1474.
  • 4Meyerzum B ii sehenfelde C, Feuerstaeke Y, Gtitze KS, et al. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituxirnab treatment. Cancer Res, 2008, 68: 5414-5422.
  • 5van der Kolk LE, Grillo-Lopez A J, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol, 2001, 115:807-811.
  • 6Hu W, Ge X, You T, et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphama cells to complement-mediated cytolysis. Cancer Res, 2011, 71: 2298-2307.
  • 7Macor P, Tripodo C, Zorzet S, et al. In viva targeting of human neutralizing antibodies against CD55 and CDs9 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res, 2007, 67: 10556-10563.
  • 8Klepfish A, Gilles L, Ioannis K, et al. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci, 2009, 1173: 865-873.
  • 9Xu W, Miao KR, Zhu DX, et al. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer, 2011,128: 2192-2201.
  • 10黎阳,屈钰华,郭海霞,吴燕峰,黄科,方建培,黄绍良,魏菁,黄燕.血清抗体及补体对利妥昔单抗介导的NK细胞杀伤Raji细胞作用的影响[J].白血病．淋巴瘤,2012,21(3):133-136. 被引量：1

二级参考文献22

  • 1达永,张伟京,苏航,陈喜林,仲凯励,余金得,俞受程.利妥昔单抗联合化疗治疗CD_(20)^+的B细胞型非霍奇金淋巴瘤27例[J].白血病．淋巴瘤,2006,15(5):371-372. 被引量：9
  • 2张文霞,郭军,林保和,孟松娘,王小沛,谢彦,郑文,张运涛,朱军.白细胞介素2增强利妥昔单抗介导的细胞毒杀伤效应机制研究[J].中华血液学杂志,2007,28(1):41-44. 被引量：1
  • 3Monton LM,Wang SS,Devesa SS,et al.Lymphoma incidence patterns by WHO subtype in United States,1992-2001.Blood,2006,107:265-276.
  • 4Coiffier B,Le page E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma.N Engl J Med,2002,346:235-242.
  • 5Pfreundschuh M,Truemper L,Osterborg A,et al.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group.The Lancet Oncol,2006,7:357-359.
  • 6Manches O,Lui G,Chaperot L,et al.In vivo mechanisms of action of rituximab on primary non-Hodgkin lymphomas.Blood,2003,101:949-954.
  • 7Cooper MA,Fehniger TA,Caligiuri MA.Human natural killer cells:a unique innate immunoregulatory role of the CD56dim subset.Blood,2001,97:3146-3151.
  • 8Cooper MA,Fehniger TA,Turner SC,et al.The biology of human natural killer-cell subsets.Trends Immunol,2001,22:633-640.
  • 9Feugier P,Van Hoof A,Sebban C,et al.Long-term results of the RCHOP study in the treatment of elderly patients with diffuse large Bcell lymphoma:a study by the Groupe d'Etude des Lymphomas del'Aduhe.J Clin Oncol,2005,23:4117-4126.
  • 10Pfrundschuh M,Trumper L,Gill D,et al.Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas:results of the NHL2B1 trial of the DSHNHL.Blood,2004,104:626-627.

共引文献2

同被引文献17

  • 1Zhao L, Xie F* Li H, et al. Combating non-Hodgkin lymphomaby targeting both CD20 and HLA-DR through CD20-243 Cross-Mab[J]. MAbs,2014,6(3) :739-747.
  • 2Zhao L, T ong Q, Qian W, et al. Eradication of non-Hodgkin lym-phoma through the induction of tumor-specific T-cell immunityby CD20-Flex BiFP[J]. Blood,2013 ,122(26) :4230-4236.
  • 3Wang SY,Racila E,Taylor RP,et al. NK-cell activation and an-tibody-dependent cellular cytotoxicity induced by rituximab-coa-ted target cells is inhibited by the C3b component of complement[J]. Blood,2008,111(3):1456-1463.
  • 4Karavitis J,Zhang M. COX2 regulation of breast cancer bone metas-tasis[J]. Oncoimmunology,2013,2(3):123-129.
  • 5Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy [J ]. Cancer Res,2007,67( 3) : 1270-1281.
  • 6Calcagno A’Rostagno R,Di Perri G. Anti-CD20 antibody thera-py for B-cell lymphomas[J]. N Engl J Med, 2012,367(9):877-[8] Rezvani AR,Maloney DG. Rituximab resistance[J]. Best PractRes Clin Haematol,2011,24(2) :203-216.
  • 7Rezvani AR,Maloney DG. Rituximab resistance[J].Best Pract Res Clin Haematol,2011,24(2) ..203-216.
  • 8Zhang C,Liu HF, Chen XH, et al. Is splenectomy necessary forimmune thrombocytopenic purpura. The role of rituximab in pa-tients with corticosteroid resistance in a single-center experience[J]. Clin Ther,2014,36(3) :385-388.
  • 9Verbrugge SE,A1 M, Assaraf YG,et al. Overcoming bortezomibresistance in human B cells by anti-CD20/rituximab-mediatedcomplement-dependent cytotoxicity and epoxy ketone-based irre-versible proteasome inhibitors[J]. Exp Hematol Oncol, 2013, 2(1):2.
  • 10Taylor RP, Lindorfer MA. Antigenic modulation and rituximabresistance[J]. Semin Hematol.2010,47(2) : 124-132.

引证文献1

二级引证文献6

白血病．淋巴瘤
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部